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TuberculosisAbstract Development assistance for health (DAH) and foreign aid have been
criticized for being poorly associated with health and economic outcomes on a
national level. This study is an attempt to examine whether DAH targeted specifi-
cally to malaria, HIV and tuberculosis (TB) is associated with changes in malaria,
HIV and TB mortality, respectively. A dataset of DAH targeted to malaria, HIV and
TB and corresponding malaria-, HIV- and TB-specific mortality was compiled for
120 low- and middle-income countries. Regression analysis was performed using
country and time-period fixed effects and control variables. While malaria and
HIV DAH were associated with reductions in malaria and HIV mortality, respectively,
TB DAH was not significantly associated with reductions in TB mortality. Estimates
were consistent in various sensitivity analyses, including generalized method of
moments estimation, addition of extra controls and analysis of a multiply imputed
dataset. In conclusion, targeted DAH is associated with reduction of HIV and malaria
mortality on a national level.
ª 2014 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
The effect of foreign aid on population-level
outcomes is controversial. Numerous aid projects
have been demonstrated to have a positive effect
42 A.J. Hsiao, C.A. Emdinat a micro-level in both the economic and health
spheres. Interventions such as vitamin A supple-
mentation, insecticide-treated nets and vaccina-
tions have been shown to reduce mortality in
randomized trials and are widely funded by foreign
donors [1].
In contrast, macro-level studies on aid have
been largely inconclusive. While a highly cited
study concluded that aid could be effective at
promoting the economic growth in the presence
of good policies [2], recent analyses have found
no relationship between aid and growth regardless
of the presence of ‘‘good’’ policies [3]. Similarly,
econometric studies that have attempted to iden-
tify whether development assistance for health
(DAH) is associated with improvements in health
outcomes have produced conflicting results. A
cross-national analysis of health aid and overall
mortality found that the provision of DAH to devel-
oping nations had no effect on population mortality
[4]. An analysis of DAH provided to African nations
for HIV control similarly found that the provision of
targeted HIV aid had no significant spillover effects
on overall mortality [5]. In contrast, a cross-
national analysis of health aid and infant mortality
found that increasing per capita health aid by $1.60
was associated with a 1.5 fewer infant deaths per
thousand births [6]. Similarly, in a cross-national
analysis of the association between health aid,
and life expectancy and under-5 mortality, a 1%
increase in health aid was associated with a
0.24 month greater increase in life expectancy
and a 0.14 per 1000 live births faster decline in
the probability of under-5 deaths per 1000 live
births [7].
These inconclusive results contrast with
modeling studies that find that donor-supported
interventions improve health outcomes on an indi-
vidual and regional level. DAH targeted toward
malaria was found to have increased coverage
rates of insecticide treated nets in Sub-Saharan
Africa from 2003 to 2008 [8]. Similarly, an analysis
of individual patient data found that individuals liv-
ing within districts receiving large amounts of HIV
assistance in Sub-Saharan Africa had lower mortal-
ity than individuals outside such districts [9].
There are a number of possible reasons for the
discrepancy between the positive findings of indi-
vidual and micro-level studies and the inconclusive
findings of macro-level studies. One possibility is
that DAH is fungible, and that the provision of
DAH to developing nations does not lead to an
increase in overall health spending [10]. Alterna-
tively, the relationship between aid and improved
outcomes may not be linked tightly enough forpoorly powered macro-analyses to detect. While
DAH may improve health outcomes on a macro-
level, broad variation in health outcomes due to
confounding factors and measurement error may
prevent regression analyses from revealing a signif-
icant relationship. As a result, the ability of health
aid to improve health outcomes may be falsely
discounted.
This possibility was examined by using a cross-
country regression analysis of development assis-
tance for health targeted specifically to malaria,
HIV and TB. It was hypothesized that the close
linkage between targeted DAH and the overall
mortality of its targeted disease would allow for
a consistent association to be observed through
fixed-effects regression analysis with various
sensitivity analyses.
2. Methods
2.1. Data and definitions
In order to estimate the association of targeted
DAH with specific health outcomes, comprehensive
datasets for both DAH and health outcomes were
aggregated. For DAH (disbursements), the Institute
for Health Metrics and Evaluation (IHME) dataset
from 1990 to 2010 was used [11]. This dataset
aggregates DAH from multiple sources, including
the Organization for Economic Cooperation and
Developments (OECD) aid database and databases
of bilateral aid agencies. Additionally, the data-
base separates DAH into that targeted toward
malaria, HIV and TB. For malaria mortality, the
IHME estimates from 1990 to 2010 were used
[12], while for TB mortality, WHO estimates from
1990 to 2010 were used. For HIV mortality, esti-
mates aggregated by UNAIDS and reported by the
WHO from 1990 to 2010 were used [13]. To control
for potential country-specific confounding factors,
a governance index (the total of six World Bank
governance indicators: control of corruption, rule
of law, regulatory quality, political stability and
absence of violence, voice and accountability and
government effectiveness), total DAH disburse-
ments, total population, population density, GDP
per capita, proportion of population aged 0–14,
proportion of population that is female, proportion
of population living in a rural area, fertility, enroll-
ment in a primary school, proportion of population
with access to adequate sanitation, natural disas-
ters, public health expenditures, out-of-pocket
health expenditures, DTP immunizations and mea-
sles immunizations were included in the dataset
[14,15]. Logarithmic transformations were used
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lation, population density and total affected by
natural disasters. Data sources are summarized in
Supplementary Tables 1, 2 and 3.
Countries were included in the analysis if they
had a population larger than 200,000 in 2010 and
were classified as a low income, low-middle
income or upper-middle income by the World Bank.
Furthermore, this analysis includes only countries
with time-series data on malaria, HIV and TB
mortality that was at least 50% complete (Supple-
mentary Table 2). The concern of selection bias
arising from this criterion was addressed in a
sensitivity analysis. As World Bank governance indi-
cators and other cross-country data were only
available after 1996, this analysis was from 1996
to 2010 (inclusive).
2.2. Model specification
To study the association between targeted
development assistance for health and disease
mortality, a longitudinal panel analysis was used.
It is noted that an ordinary least squares regression
may yield biased estimates because of determi-
nants of mortality that are unobserved in this data-
set. To reduce this source of bias, a country and
time-period fixed-effects model was used to
capture country-specific and time-period-specific
characteristics that account for disease mortality.
The following model was used for malaria
mortality:
logðmalaria mortalityi;tÞ ¼ ai þ dlogðDAH malariai;t1Þ
þ b1logðDAH HIVi;t1Þ
þ b2logðDAH TBi;t1Þ
þ b3ðgovernancei;tÞ
þ b4logðGDPi;tÞ
þ b5logðpopulationi;tÞ
þ b6logðpopulation densityi;tÞ
þ lt þ eit ð1Þ
where ai is a country-specific fixed effect capturing
unobserved, time-invariant country characteris-
tics; DAHmalaria is DAH targeted to malaria; DAHHIV
and DAHTB are DAH targeted to HIV and TB,
respectively; governance is an index measure cal-
culated using World Bank governance indicators;
GDP, population and population density are
additional controls; lt are time-period fixed
effects and eit is the error term. The coefficient
of interest is d, which represents the percent
change in malaria DAH associated with a 1% change
in malaria mortality; the fixed-effects model
means that this relationship is estimated usingwithin-country, within-time-period variation in
DAH.
Similar models were used for HIV and TB. The
dependent variable for all models was disease
mortality (for malaria, HIV or TB) in time period
t; the independent variables included DAH
(malaria, HIV and TB all included) for time period
t  1 and controls for time period t. The lagged
time period for DAH is consistent with the
literature and was chosen on the assumption that
a certain amount of time would be necessary to
disburse DAH and therefore affect disease mortal-
ity. Additionally, a lagged independent variable is
sequentially exogenous to disease mortality,
reducing potential bias.
For all analyses, malaria, HIV and TB mortality
per capita and DAH per capita were averaged over
3 year period in order to minimize year-to-year
variation and reduce measurement error, as consis-
tent with other cross-country analyses of foreign
aid [2,3]. Logarithmic transformations of disease
mortality, DAH, GDP, population, population
density and lagged mortality were used to satisfy
normality assumptions of regression. The main
regression analysis was performed with the removal
of outliers in development assistance for health,
defined as the largest 1% of values. A summary of
the data points used is provided (Table 1).
2.3. Sensitivity analyses
A series of sensitivity analyses were performed to
test the robustness of the results. First, generalized
method of moments (GMM) estimation was used to
address the concern that the inclusion of a lagged
dependent variable in a fixed-effects model yields
biased estimates across all estimated coefficients.
The issue arises because fixed-effects estimation
requires demeaning at the country level, and
the demeaned error term necessarily depends on
the error terms from each time period; the lagged
dependent variable is correlated with the lagged
error term and thus not exogenous to the demeaned
error term. GMM estimation relies on the weaker
assumption of predetermination to estimate the
effect using lagged variables as instruments. GMMs
instrumental-variable approach also addresses bias
arising from time-varying, country-specific unob-
servables (i.e., those not captured by country and
time-period fixed effects), as well as classical
measurement error. Mishra and Newhouse imple-
ment a similar application of GMM estimation [7].
This system was used over first-difference GMM
because of the persistent nature of the dependent
variable [16,17].
Table 1 Country and time-period fixed effects regression analysis of disease mortality and targeted DAH with control
variables and lagged mortality.
Variables (1) (2) (3)
log(Malaria mortality) log(HIV mortality) log(TB mortality)
log(Lagged Malaria DAH per capita) 0.257*** 0.0263 0.0918
(0.0804) (0.139) (0.104)
log(Lagged HIV DAH per capita) 0.0623** 0.245*** 0.000971
(0.0289) (0.0556) (0.0365)
log(Lagged TB DAH per capita) 0.0468 0.218 0.119
(0.120) (0.220) (0.144)
Governance1 0.00293 0.00153 0.00396
(0.00751) (0.0152) (0.0108)
log(GDP) 0.0674 0.405*** 0.227**
(0.0652) (0.132) (0.0949)
log(Population) 0.745 1.988 1.359
(1.193) (1.279) (0.998)
log(Population Density) 1.289 1.413 1.581
(1.177) (1.403) (1.061)
log(Previous Mortality) (Lagged) 0.779*** 0.685*** 0.624***
(0.0425) (0.0367) (0.0711)
Country fixed effects Yes Yes Yes
Period fixed effects Yes Yes Yes
Country-periods 474 460 584
R-squared 0.998 0.99 0.988
Number of countries 99 94 120
Standard errors (in parentheses) are heteroskedasticity and autocorrelation robust, clustered by country.
1 Total of six World Bank governance indicators.
** p < 0.05.
*** p < 0.01.
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of the population aged 0–14, proportion that is
female, proportion living in rural areas, fertility
rate, school enrollment, proportion of the popula-
tion with access to adequate sanitation, log of pop-
ulation affected by a natural disaster, percentage
of public expenditures on health, percentage of
private expenditures on health, percentage of
children aged 12–23 months with DPT immuniza-
tion and percentage of children aged 12–23 months
with measles immunization) were introduced into
the model to address further concerns of omitted
variable bias. Thirdly, total DAH disbursements
were added to account for the investment in the
health system infrastructure at large, as well as
to assess the relative contribution of disease-
specific DAH. Fourthly, the model was tested with
the inclusion of the 1% outliers in DAH excluded
in the main regression analysis. Fifthly, the time
period under investigation was restricted to
2000–2010, as much of the early IHME DAH dataset
is imputed [18]. Sixthly, potential selection bias
arising from missing data was addressed using mul-
tiple imputation based on chained equations; ten
imputed datasets were generated, fixed-effectsregression was performed on each and estimates
were pooled. Finally, to address the concern of
bias resulting from the fact that modeled estimates
of malaria, TB and HIV mortality indirectly rely
upon DAH, further analyses were performed using
an alternative set of outcome measures: reported
malaria deaths (World Health Organization/World
Malaria Report), reported TB cases (World Health
Organization/Global Tuberculosis Report) and esti-
mated HIV prevalence (UNAIDS/World Health
Organization).
All analyses were performed using STATA version
12 (STATA Corp.).
3. Results
Within this sample of 120 low- to middle-income
countries, DAH increased rapidly from 1990 to
2000. In 1991, DAH for HIV and malaria was less
than $0.01 per capita and DAH was $0.013 per
capita for TB (Fig. 1). By 2010, DAH targeted to
malaria was $0.25 per capita, a more than 50-fold
increase. These trends were paralleled in HIV and
TB, with DAH for TB increasing to $0.11 per capita
by 2010 and HIV DAH increasing to $0.88 (Fig. 1B
A 
C 
B 
Fig. 1 Development assistance for health (2005 $US
per capita) and disease mortality (per 100,000 popula-
tion) for (A) malaria, (B) HIV and (C) tuberculosis from
1990 to 2010.
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the period from 2005 to 2010, over which the larg-
est increase in DAH was observed. However, forboth malaria and HIV, this decline in mortality
followed a significant increase in mortality from
1990 to 2005 (Fig. 1A and C).
In order to further examine the relationship
between DAH and mortality, a country and
time period fixed effects regression analysis was
implemented.
3.1. Association between targeted DAH and
disease mortality
It was examined whether or not DAH was associ-
ated with a decrease in mortality with country-
level controls (governance, GDP, population and
population density). For malaria mortality (column
1, Table 1), it was found that malaria DAH is highly
predictive of a decrease in mortality (p = 0.002),
while HIV DAH is significant but less strongly corre-
lated, and tuberculosis DAH is insignificant. For HIV
mortality (column 2, Table 1), only HIV DAH is pre-
dictive of a decrease in HIV mortality (p < 0.001).
Conversely, TB DAH is not predictive of a decrease
in TB mortality (p = 0.41). Thus, it appears that
while malaria DAH and HIV DAH are associated with
a decrease in malaria mortality and HIV mortality
on a country level, TB DAH is not. A 50% increase
in DAH targeted to malaria would be associated
with a 9.9% (95% CI 4.0%, 15.5%) decrease in
malaria mortality. A 50% increase in DAH targeted
to HIV would be associated with a 9.5% (CI 5.4%,
13.4%) decrease in HIV mortality.
3.2. Sensitivity analyses
A series of sensitivity analyses were performed to
test the robustness of the results. When GMM
regression analysis was performed using two fur-
ther lags of DAH and control variables, malaria
DAH and HIV DAH were again associated with
reductions in malaria and HIV mortality, respec-
tively (Table 2). Specifically, one-period lagged
malaria DAH was significantly associated, while
three-period lagged HIV DAH was significant for
HIV mortality (i.e., HIV DAH from 6 to 9 years
prior). Although three-period lagged TB DAH was
significant in this specification, this was not
observed in further analyses.
When extra controls (proportion of the popula-
tion aged 0–14, proportion that is female, propor-
tion living in rural areas, fertility rate, school
enrollment, proportion of the population with
access to adequate sanitation, log of population
affected by a natural disaster, public expenditure
on healthcare, out-of-pocket expenditure on
healthcare, DPT immunization and measles
immunization) were introduced, malaria DAH and
Table 2 Arellanno-Bond GMM regression analysis of disease mortality and targeted DAH. Model includes current, single-
lagged and double-lagged log(GDP), governance, log(population) and log(population density) as control variables. DAH per
capita refers to targeted DAH, i.e., malaria DAH for specification 1 and HIV DAH for specification 2.
Variables (1) (2) (3)
log(Malaria mortality) log(HIV mortality) log(TB mortality)
log(One-period lagged DAH per capita) 0.228** 0.0403 0.215
(0.111) (0.0891) (0.236)
log(Two-period lagged DAH per capita) 0.0799 0.00476 0.0286
(0.184) (0.131) (0.215)
log(Three-period lagged DAH per capita) 0.0209 0.259** 0.265**
(0.134) (0.127) (0.129)
Hansen test(p-value) 0.156 0.498 0.491
Number of instruments 67 67 67
Number of countries 97 93 119
Number of observations 285 279 352
Standard errors (in parentheses) are heteroskedasticity robust and finite-sample corrected.
** p < 0.05.
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decreases in malaria and HIV mortality, respec-
tively (Supplementary Table 4). Estimates were
consistent when total DAH was introduced into
the model as a covariate (Supplementary Table 5).
Estimates were also consistent when outliers were
included (Supplementary Table 6) and when the
period of analysis was restricted to 2000–2010
(Supplementary Table 7). When multiple imputa-
tion using chained equations was used to impute
missing data points, HIV and malaria DAH remained
significantly negatively associated with HIV and
malaria mortality (Supplementary Table 8). When
reported malaria deaths, reported TB cases and
estimated HIV prevalence were used in place of
estimated mortality, malaria DAH and HIV DAH
were associated with reduced reported malaria
deaths and estimated HIV prevalence with the
addition of extra controls (Supplementary Table 9).
Malaria DAH was imprecisely estimated with
reported deaths in the basic specification, but the
estimated coefficient took the expected sign and
was significant with extra controls. Throughout all
specifications, TB DAH remained insignificant.
4. Discussion
These results illustrate that at the country level
DAH targeted to malaria and HIV are associated
with reductions in malaria and HIV mortality,
respectively. These results are the first demonstra-
tion that targeted DAH on a national level that is
associated with reduced disease mortality. These
results contradict previous studies that found no
evidence of a relationship between aggregatehealth aid and population-level mortality [4,5]
and support an analysis by Mishra and Newhouse
which demonstrated a significant association
between DAH and decreased infant mortality [6].
It is acknowledged that the lack of an association
between targeted aid and health outcomes is not
implausible. A previous analysis found that for
every $1 provided in the form of DAH, governments
reduced their domestic health spending by $0.46
[10]. It is possible that nations that received tar-
geted DAH reduced domestic spending on target
diseases to such a degree that no improvement in
health outcomes could be observed. However,
these results indicate that, at least for HIV and
malaria, this hypothesis is not supported.
Interestingly, the GMM estimates suggest that
three-period lagged HIV DAH (i.e.,6–9 years prior
to current HIV mortality) was significantly associ-
ated with decreased HIV mortality, while single-
period lagged malaria DAH was associated with
reduced malaria mortality. This is consistent with
the known epidemiology of malaria and HIV. Unlike
malaria, in which the increased uptake of insecti-
cide treated nets and anti-malarials would immedi-
ately reduce mortality, changes in the incidence of
HIV via greater uptake of antiretroviral therapy
would lead to a delayed impact on HIV mortality
(in addition to an immediate benefit from the
treatment of the HIV-positive) [19].
However, unlike DAH for malaria and HIV, DAH
for TB was not associated with reductions in TB
mortality. One explanation is the proportion of
domestic spending allocated to TB relative to inter-
national support. In 2011, 90% of spending on TB
control in developing countries was provided by
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50% of spending in developing countries was pro-
vided by domestic sources, and only 36% in Africa
[21]. Similarly, domestic malaria financing was
estimated to make up only 25% of global funding
for malaria control in 2010 [22]. Unlike the effects
of malaria and HIV DAH on mortality, the effect of
TB DAH on TB mortality would be heavily out-
weighed by changes in domestic spending on TB.
In this way, the observed heterogeneity of the
aid-mortality effect further supports the need to
examine the data at the disease-specific level.
In spite of these positive findings, these results
cannot be interpreted as having demonstrated cau-
sality between increased DAH and improvements in
health outcomes. Although this study has demon-
strated an association between malaria and HIV
DAH and reductions in their respective mortality,
a causal relationship is not the sole explanation.
Another possibility is that DAH follows improve-
ments in outcomes rather than the other way
around. Although lagged DAH was utilized relative
to mortality and GMM estimation in an attempt to
address this possibility, lagged DAH may still be
associated with past performance, which itself
may be associated with future performance. A sec-
ond potential source of bias is time-associated
measurement error in DAH. If reporting of DAH sys-
tematically improved over time, the effect of mea-
sured DAH on mortality may be underestimated, as
the observed increase in DAH over a given period
would be an overestimate of the true increase in
DAH. Finally, unobserved confounding and selec-
tion bias may also have impacted these results,
although the GMM analysis represents a modest
attempt to address these concerns as well.
In sum, unlike previous aid-growth studies that
have found a negative association between aid
and growth before the addition of controls and a
non-significant relationship after the addition of
controls [3], it was found that targeted DAH for
malaria and HIV are associated with reductions in
mortality (columns 1 and 2, Table 1) and that this
effect is robust to a variety of sensitivity checks,
including GMM estimation, expanded controls,
and multiple imputations of missing data. It is also
consistent with numerous case studies that have
found that donor funding saves lives [1] and that
the withdrawal of donor funding has led to the
resurgence of disease [23].
In light of these findings, the global slowdown in
DAH is concerning. While DAH grew at a rate of 17%
from 2007 to 2008, this rate slowed to 4% from
2010 to 2011 (1% if loans are excluded). Since
2000, broad gains have been made in the fightagainst malaria, HIV and TB, as shown in Fig. 1
[24]. However, significant budgetary shortfalls
exist for the control of all three diseases, a trend
that will be exacerbated by both the slowdown in
funding and the continuing increase in the preva-
lence of HIV. As these findings and a larger body
of work suggest, development assistance for health
may be associated with reductions in preventable
mortality from infectious disease.
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